Level, N.M., “High Drug Costs Outweigh ‘Medicare for All’ as Top Health-care Issue for Voters,” LA Times, available at <https://www.latimes.com/politics/story/2020-01-21/high-cost-prescription-drugs-campaign-issue> (last visited February 27, 2020).+(last+visited+February+27,+2020).>Google Scholar

Kesselheim, A.S., Avorn, J., and Sarpatwari, A., “The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform,” JAMA 316, no. 8 (2016): 858–871.CrossRefGoogle Scholar

Wineinger, N.E., Zhang, Y., and Topol, E.J., “Trends in Prices of Popular Brand-Name Prescription Drugs in the United States,” JAMA Network Open 2, no. 5 (2019): e194791.CrossRefGoogle Scholar

Global oncology trends 2019, IQVIA Institute for Human Data Science, available at <https://www.iqvia.com/insights/the-iqvia-institute/reports/global-oncology-trends-2019> (last visited February 27, 2020).+(last+visited+February+27,+2020).>Google Scholar

Pharmaceutical company drug sales as compared to R&D outlays, Knowledge Ecology International, available at <http://drugdatabase.info/pharmaceutical-company-drug-sales-as-compared-to-rd-outlays/> (last visited February 27, 2020).+(last+visited+February+27,+2020).>Google Scholar

Galkina, C.E., Beierlein, J.M., Khanuja, N.S., McNamee, L.M., and Ledley, F.D., “Contribution of NIH Funding to New Drug Approvals 2010-2016,” Proceedings of the National Academy of Sciences of the USA 115, no. 10 (2018): 2329–2334.Google Scholar

Larsen, J.C. and Disbrow, G.L., “Project BioShield and the Biomedical Advanced Research Development Authority: A Ten Year Progress Report on Meeting U.S. Preparedness Objectives for Threat Agents,” Clinical Infectious Diseases 64, no. 10 (2017):1430–1434; Kaiser, J., “Texas Voters Approve Second Life for State Cancer Funding Agency,” Science, available at <https://www.sciencemag.org/news/2019/11/texas-voters-approve-second-life-state-cancer-funding-agency> (last visited February 27, 2020).Google Scholar

Nayak, R., Avorn, J., and Kesselheim, A.S., “Public Sector Financial Support for Late Stage Discovery of New Drugs in the United States: Cohort Study,” BMJ 367 (2019): l5766.Google Scholar

Sarpatwari, A., LaPidus, A.K., and Kesselheim, A.S., “Revisiting the National Institutes of Health Fair Pricing Condition: Promoting Drugs Developed with Government Support,” Annals of Internal Medicine (2020)(E-pub ahead of print).CrossRefGoogle Scholar

Kesselheim, A.S., Avorn, J., and Sarpatwari, A., “The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform,” JAMA 316, no. 8 (2016): 858–871.Google Scholar

Swanson, A., “Big Pharmaceutical Companies are Spending Far More on Marketing than Research,” Washington Post, available at <https://www.washingtonpost.com/news/wonk/wp/2015/02/11/big-pharmaceutical-companies-are-spending-far-more-on-marketing-than-research> (last visited February 27, 2020).+(last+visited+February+27,+2020).>Google Scholar

Lazonick, W., Hopkins, M., Jacobson, K., Sakinç, M.E., and Tulum, O., “US Pharma's Financialized Business Model,” Institute for New Economic Thinking, available at <https://www.ineteconomics.org/uploads/papers/Final-WP_60-Lazonick-et-al.-USPharma-Business-Model-sept-8.pdf> (last visited February 27, 2020). (last visited February 27, 2020).' href=https://scholar.google.com/scholar?q=Lazonick,+W.,+Hopkins,+M.,+Jacobson,+K.,+Sakinç,+M.E.,+and+Tulum,+O.,+“US+Pharma's+Financialized+Business+Model,”+Institute+for+New+Economic+Thinking,+available+at++(last+visited+February+27,+2020).>Google Scholar

Kaltenboeck, A., Calsyn, M., Frederix, G.W.J., et al., “Grounding Value-Based Drug Pricing in Population Health,” Clinical Pharmacology & Therapeutics (2020) (E-pub ahead of print).Google Scholar

Dunn, A., “Amgen Exists Neuroscience R&D as Pharma Pulls Back from Field,” BioPharma Dive, available at <https://www.biopharmadive.com/news/amgen-exits-neuroscience-rd-as-pharma-pulls-back-from-field/566157/> (last visited March 13, 2020).+(last+visited+March+13,+2020).>Google Scholar

World Health Organization, “Lack of New Antibiotics Threatens Global Efforts to Contain Drug-Resistant Infections,” available at <https://www.who.int/news-room/detail/17-01-2020-17-01-2020-lack-of-new-antibiotics-threatens-global-efforts-to-contain-drug-resistant-infections> (last visited February 27, 2020).+(last+visited+February+27,+2020).>Google Scholar

World Health Organization, 2019 Antibacterial Agents in Clinical Development: An Analysis of the Antibacterial Clinical Development Pipeline, available at <https://apps.who.int/iris/bitstream/handle/10665/330420/9789240000193-eng.pdf> (last visited February 27, 2020).+(last+visited+February+27,+2020).>Google Scholar

Baker, D., “The Future of the Pharmaceutical Industry: Beyond Government-Granted Monopolies,” CEPR, available at <http://cepr.net/images//stories/reports/pharma-industry-2019-03.pdf> (last visited February 27, 2020).+(last+visited+February+27,+2020).>Google Scholar

“Savings Available under Full Generic Substitution of Multiple Source Brand Drugs in Medicare Part D,” U.S. Department of Health and Human Services, available at <https://aspe.hhs.gov/system/files/pdf/259326/DP-Multisource-Brands-in-Part-D.pdf?utm_source=newsletter&utm_medium=email&utmcampaign=newsletter_axiosvitals&stream=top> (last visited February 27, 2020).+(last+visited+February+27,+2020).>Google Scholar

Mazzucato, M., The Entrepreneurial State: Debunking Public vs. Private Sector Myths (New York, NY: Public Affairs; 2015).Google Scholar